A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration (“FDA”) approved ZEVASKYN® (prademagene zamikeracel) gene-modified cellular sheets, also known as ZEVASKYN®, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (“RDEB”), a serious and debilitating genetic skin disease. There is no cure for RDEB, and ZEVASKYN® is the only FDA-approved product to treat RDEB wounds with a single surgical application. ZEVASKYN® was granted Orphan Drug and Rare Pediatric Disease designations by the FDA ZEVASKYN® is manufactured at our current Good Manufacturing Practices (“cGMP”) manufacturing facility in Cleveland, Ohio.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | 71M | 71M | -64M | -54M | -43M | -85M |
| EPS | $1.01 | $1.01 | $-1.55 | $-2.53 | $-5.53 | $-21.50 |
| Free Cash Flow | 68M | 68M | -58M | -37M | -44M | -70M |
| ROIC | -75.7% | 63.5% | -111.7% | -58.2% | -162.5% | -117.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.23 | 0.23 | 0.66 | 0.67 | 0.29 | 0.22 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -89M | -89M | -64M | -47M | -51M | -90M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 44.7% | 70.0% | -144.7% | -365.5% | -162.5% | -117.2% |
| Shares Outstanding | 70M | 70M | 41M | 49M | 27M | 0M |
ABEONA THERAPEUTICS INC. passes 0 of 9 quality checks, indicating weak fundamentals.
ABEONA THERAPEUTICS INC. (ABEO) has a 5-year average return on invested capital (ROIC) of -77.2%. This is below average and may indicate limited pricing power.
ABEONA THERAPEUTICS INC. (ABEO) has a market capitalization of $357M. It is classified as a small-cap stock.
ABEONA THERAPEUTICS INC. (ABEO) does not currently pay a regular dividend.
ABEONA THERAPEUTICS INC. (ABEO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ABEONA THERAPEUTICS INC. (ABEO) generated $68 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ABEONA THERAPEUTICS INC. (ABEO) has a debt-to-equity ratio of 0.23. This indicates a conservatively financed balance sheet.
ABEONA THERAPEUTICS INC. (ABEO) reported earnings per share (EPS) of $1.01 in its most recent fiscal year.
ABEONA THERAPEUTICS INC. (ABEO) has a return on equity (ROE) of 70.0%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 16 years of financial data for ABEONA THERAPEUTICS INC. (ABEO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ABEONA THERAPEUTICS INC. (ABEO) has a book value per share of $2.26, based on its most recent annual SEC filing.